Savara (NASDAQ:SVRA) Reaches New 12-Month High Following Analyst Upgrade

Savara Inc. (NASDAQ:SVRA)’s share price reached a new 52-week high during mid-day trading on Thursday after JMP Securities raised their price target on the stock from $8.00 to $11.00. JMP Securities currently has a market outperform rating on the stock. Savara traded as high as $4.42 and last traded at $4.24, with a volume of 127650 shares. The stock had previously closed at $4.11.

SVRA has been the subject of several other reports. Guggenheim increased their target price on shares of Savara from $8.00 to $11.00 and gave the stock a “buy” rating in a report on Tuesday, September 9th. Oppenheimer increased their target price on shares of Savara from $6.00 to $8.00 and gave the stock an “outperform” rating in a report on Monday, September 8th. Lifesci Capital raised shares of Savara to a “strong-buy” rating in a report on Tuesday, October 14th. Wells Fargo & Company began coverage on shares of Savara in a report on Monday. They issued an “overweight” rating and a $7.00 target price for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Savara has a consensus rating of “Moderate Buy” and an average price target of $7.83.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Prudential Financial Inc. bought a new stake in shares of Savara in the second quarter worth about $30,000. BNP Paribas Financial Markets grew its holdings in Savara by 52.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock valued at $31,000 after buying an additional 4,626 shares in the last quarter. May Hill Capital LLC purchased a new position in Savara during the 2nd quarter valued at approximately $32,000. Brevan Howard Capital Management LP purchased a new stake in shares of Savara during the 2nd quarter worth approximately $33,000. Finally, Quadrature Capital Ltd purchased a new stake in shares of Savara during the 2nd quarter worth approximately $42,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Stock Up 0.2%

The business has a 50-day moving average price of $3.50 and a 200 day moving average price of $2.92. The company has a current ratio of 11.08, a quick ratio of 11.08 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $712.10 million, a P/E ratio of -8.24 and a beta of 0.46.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02). On average, equities analysts expect that Savara Inc. will post -0.45 EPS for the current fiscal year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.